Peptides for men's sexual function — the integrated landscape

These are not the same thing. The distinction matters because the mechanisms are different and the conversations that follow are different.

Sexual function in men is a multi-system process. Desire — libido — is driven primarily by the central nervous system, by testosterone acting on brain regions including the hypothalamus and limbic system, and by dopaminergic reward pathways. It's influenced by mood, by energy, by sleep, by what's happening in the relationship, and by where the nervous system sits on the sympathetic-parasympathetic axis at any given moment. Arousal — the physiological process of genital engorgement and sensitivity — involves the central melanocortin system, which registers sexual cues and initiates the downstream cascade, and the peripheral vascular system that delivers the blood flow response. Erection specifically is a vascular and neurological event: nitric oxide released from endothelial cells and cavernous nerve endings relaxes smooth muscle in the corpus cavernosum, blood flows in, vascular pressure increases, and outflow is occluded. The system requires healthy endothelium, adequate nitric oxide production, intact nerve supply, and a central nervous system that's not actively suppressing the signal. Ejaculation and orgasm involve a separate set of spinal cord reflexes, sympathetic activation, and central processing. Each of these can be disrupted independently, and understanding which one is involved is what makes a clinical evaluation more useful than a supplement protocol.

Erectile dysfunction is the most common and most talked-about concern, and it has its own internal spectrum. Vascular ED — the most common type in men over forty — reflects endothelial dysfunction and reduced nitric oxide bioavailability. The same pathology that drives early atherosclerosis drives vascular ED, which is why men with ED have elevated rates of subclinical cardiovascular disease and why an ED diagnosis in a man in his forties is now considered a harbinger that warrants cardiovascular risk evaluation, not just a urological inconvenience. Venous leak, where outflow occlusion is inadequate, is a structural variant. Neurogenic ED follows nerve damage from diabetes, pelvic surgery, or other causes. Central ED reflects insufficient arousal signal from the brain rather than a peripheral execution problem. Psychogenic ED is real and coexists with physiological contributors; performance anxiety becomes its own perpetuating mechanism in ways that are neurologically distinct from simply feeling nervous.

Low libido is usually hormonal until proven otherwise. Testosterone is the primary driver of sexual desire in men — not the only driver, but the dominant one — and declining testosterone with age (gradual andropause), or more acute hypogonadism from various causes, reliably produces reduced libido as a core symptom. Elevated prolactin, which can result from a pituitary adenoma or from dopamine-suppressing medications, specifically suppresses libido and can cause ED through gonadotropin suppression. Thyroid dysfunction — both hypo and hyper — affects sexual function. Elevated estradiol relative to testosterone (common in men with obesity or significant visceral fat, where aromatase activity converts testosterone to estrogen peripherally) can suppress libido and contribute to ED. The workup matters: total and free testosterone, LH and FSH to distinguish primary from secondary hypogonadism, prolactin, thyroid panel, estradiol, glucose and metabolic markers. A provider who hands a man a PDE5 inhibitor without any lab evaluation is missing the clinical opportunity.

The medication review is often the most underutilized diagnostic step. SSRIs and SNRIs are the most common pharmacological cause of sexual dysfunction in otherwise-healthy men — they affect desire, arousal, and orgasm through serotonergic mechanisms, and the effect can be severe enough to undermine treatment adherence. This is documented, common, and frequently not addressed because neither the prescribing provider nor the patient raises it. Beta-blockers affect sexual function. Finasteride for hair loss or prostate has a real sexual side-effect profile in a subset of men that is more persistent in some cases than the FDA labeling suggests. Antipsychotics suppress prolactin-mediated pathways. Opiates profoundly suppress testosterone. If you take any of these and have noticed changes in sexual function, the medication connection is worth raising explicitly.

Against this landscape, the management hierarchy becomes clearer. PDE5 inhibitors — sildenafil, tadalafil — are first-line for vascular and mixed-etiology ED, and their evidence base is the strongest in the field. They work by inhibiting the enzyme that degrades cyclic GMP, which is the downstream mediator of nitric oxide's vasodilatory effect — essentially amplifying the nitric oxide signal and sustaining the erection response. They're effective, generally well-tolerated, and available at accessible price points as generics. Testosterone replacement therapy addresses hypogonadism-related libido suppression, ED in the context of low testosterone, and often improves energy, mood, and body composition as collateral effects. The decision to start TRT involves a full clinical picture including symptoms, labs, and discussion of fertility implications with a prescribing provider. Penile rehabilitation after prostate surgery, involving regular PDE5 inhibitor use and sometimes vacuum erection device therapy, is an established approach. Peyronie's disease — structural plaque formation in the tunica albuginea causing penile curvature and often painful erections — has specific FDA-approved treatment with collagenase clostridium histolyticum (Xiaflex) for appropriate-stage disease, and surgical options for more advanced cases.

Where peptides enter this picture with the most evidence and the clearest mechanism is PT-141, generic name bremelanotide. PT-141 is a synthetic analog of alpha-MSH that acts as a melanocortin receptor agonist, specifically at MC3R and MC4R receptors in the brain. These receptors are part of the central melanocortin system that mediates sexual arousal at the level of the nervous system — upstream of the vascular mechanism that PDE5 inhibitors address. Bremelanotide received FDA approval in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, which gives it the unusual distinction of being the only approved pharmacological treatment for central arousal — a low-desire state driven by insufficient central signal rather than inadequate peripheral execution. In men, PT-141 is used off-label by prescribing providers for central arousal issues, typically in the context of reduced libido that doesn't respond adequately to testosterone optimization alone, or in men who have adequate vascular response but reduced central desire. Because its mechanism is central rather than peripheral, it complements rather than overlaps with PDE5 inhibitors: a man who has ED from vascular causes benefits from tadalafil; a man who has adequate erection capacity but low central arousal may benefit from PT-141; a man with both issues has a reason to consider both in conversation with his prescribing provider. PT-141 has a side-effect profile that includes nausea and transient increases in blood pressure, and it requires clinical evaluation before use.

Kisspeptin-10 and its analogs represent an upstream approach to the HPG axis. Kisspeptin is the neuropeptide that drives GnRH release from the hypothalamus, which drives LH and FSH release from the pituitary, which drive testicular testosterone production and function. Research has explored kisspeptin administration for its potential to stimulate the HPG axis, particularly in the context of hypogonadotropic hypogonadism — the form where the axis is insufficiently signaling rather than where the testes themselves are failing. This is primarily research territory; kisspeptin analogs are not yet approved or standard of care, and the clinical application is being explored in academic centers. The preclinical and early human research is interesting for its mechanistic clarity about upstream HPG regulation.

HCG and gonadorelin occupy a more established practical role for men on TRT who want to maintain testicular function, intratesticular testosterone, and fertility potential. Exogenous testosterone suppresses LH, which stops testicular stimulation, which leads to testicular atrophy and impaired spermatogenesis. HCG mimics LH and maintains testicular stimulation in the face of exogenous testosterone suppression; gonadorelin (synthetic GnRH) stimulates the pituitary to continue LH and FSH output through the hypothalamic pathway. Both are used in clinical TRT protocols to preserve testicular volume and fertility, and their relevance to sexual function is that intratesticular testosterone — which HCG helps maintain — contributes to aspects of sexual response beyond what circulating testosterone alone provides.

BPC-157 has been researched in preclinical models for its effects on vascular healing and endothelial function, upregulation of nitric oxide synthase, and smooth muscle relaxation in vascular beds — mechanisms that are theoretically relevant to erectile function given how vascular the process is. This research is primarily animal-model data, and the translation to human erectile function has not been established in controlled trials. It's a plausible mechanistic thread, not a clinical conclusion. GH-axis peptides like Sermorelin affect sleep architecture, and the relationship between sleep quality and sexual function is direct and underappreciated: testosterone is secreted predominantly during sleep, particularly slow-wave sleep, and chronic sleep deprivation suppresses morning testosterone in ways that are measurable. Supporting sleep quality through GH-axis peptide approaches may help support the testosterone production environment as an indirect benefit.

The relationship context is real and not separate from the biology. Performance anxiety drives sympathetic activation, which is physiologically opposed to the parasympathetic state required for erection. This isn't psychological weakness — it's an autonomic fact, and it creates a cycle where a single failure event increases anxiety that increases failure probability. Addressing this cycle sometimes requires approaches that aren't in the lab workup: honest conversations with a partner, sometimes sex therapy, sometimes the use of a PDE5 inhibitor not because the mechanism is primarily vascular but because it raises the floor of confidence enough to interrupt the anxiety cycle. This is legitimate clinical strategy, not admission of defeat.

The integrated picture that a urologist or men's sexual health specialist evaluates includes all of this: the hormonal context, the cardiovascular risk picture, the medication review, the psychological and relationship layer, and then the specific interventions matched to the specific mechanisms. Peptide approaches — PT-141 for central arousal, GH-axis support for sleep and the testosterone production environment, potentially BPC-157 for vascular function as research develops — are adjunctive tools within a larger clinical picture. They're worth knowing about. They're not where the evaluation starts.

What matters most, practically, is finding a clinician who takes this comprehensively: who runs the labs rather than just writing the prescription, who reviews the medications, who addresses TRT if indicated with attention to testicular preservation, who understands the central versus peripheral distinction in arousal, and who doesn't dismiss the relationship and psychological layer as outside their scope. That comprehensive evaluation is where the meaningful leverage lives. Peptide considerations extend the toolkit from there.